CytoDyn Alerts Shareholders to Vote on Company’s Proxy Card Ahead of October 28th Annual Meeting
VANCOUVER, Wash .-- (BUSINESS WIRE) - CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Firm”), a late-stage biotechnology firm growing Leronlimab, a CCR5 antagonist with potential for a number of therapeutic indications, right now…